The European Medicines Agency (EMA), the EU's drug regulator, has approved the use of Pfizer (NYSE:PFE)-BioNTech's (Nasdaq:BNTX) COVID-19 vaccine for children between the ages of five and 11, Reuters news agency reported on Thursday.
The EMA has recommended that the vaccine, which is called Comirnaty, will be given in two doses of 10 micrograms three weeks apart as an injection in the upper arm. Adult doses contain 30 micrograms.
The EMA said: "The benefits of Comirnaty in children aged five to 11 outweigh the risks, particularly in those with conditions that increase the risk of severe COVID-19."
According to the companies, their vaccine showed 90.7% efficacy against COVID-19 in a clinical trial of children aged five to 11.
While final approval is up to the European Commission, it typically follows EMA recommendations.
Tens of millions of children in this age group will be eligible for the shot in the EU, Reuters noted.
Egetis receives US notice of allowance for MCT8 deficiency composition patent
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117